Midatech Pharma (MTPH LN)

Analysis

Health Care • United Kingdom

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of target therapies for various diseases with unmet needs. It offers Zuplenz, an oral soluble film for chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral rinse gel, for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the prevention of breast cancer. The company is also developing a pipeline of clinical and preclinical product candidates focused on therapeutic areas of cancer; endocrine disorders, such as diabetes; and immunotherapy for autoimmune diseases. The company was founded in 2000 and is based in Abingdon, the United Kingdom.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now